Brazil's expanding role in global medical research may increase local access to cutting-edge treatments and stimulate economic growth. This basket provides exposure to the theme through US and EU-listed companies that supply critical services and infrastructure for clinical trials in the region.
Published on November 3
Brazil's clinical trial sector is expanding rapidly as global pharmaceutical companies recognise the country's potential. This growth could benefit the infrastructure companies that make these trials possible.
These established US and EU companies offer exposure to Brazil's growth story whilst maintaining the stability of developed market listings. It's a smart way to access emerging opportunities with reduced direct country risk.
From lab equipment to data management, these companies provide the critical backbone for clinical research. As Brazil's trial ecosystem grows, demand for their specialised services should follow.
Brazil is becoming a major hub for global clinical trials, thanks to its large, diverse population and improving regulatory environment. This creates opportunities in the life sciences sector as more pharmaceutical companies choose Brazil for their research studies. We've identified this trend as a way to invest in the growing healthcare research infrastructure.
This group focuses on established US and EU-listed companies rather than direct Brazilian investments, providing geographic diversification whilst still capturing the growth theme. These companies provide essential services like trial management, laboratory equipment, and data handling that make clinical research possible in Brazil.
Each company was selected for its significant role in the clinical trial ecosystem and established operations in Brazil. From contract research organisations that manage studies to specialised equipment manufacturers and logistics providers, these firms are the backbone that enables Brazil's expanding medical research sector.
Summary of basket market capitalisation and investor takeaways.
IQV: $36.86B
ICLR: $13.12B
MEDP: $16.48B
Get the full story on this Basket. Read our detailed article on its risks and potential.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
Home Depot's recent earnings beat highlights consistent consumer spending on smaller household repair and maintenance projects. This ongoing trend presents promising opportunities for various home improvement retailers and building material suppliers.
+1
Here are a few of the assets in this group. Create an account to unlock the full list.
Join Nemo FREE today and unlock every stock
It only takes 60 seconds.
10 of 11 assets in this group are rated Buy by professional analysts.
